The Science Behind Digestive Health Supplements

Therapeutic dose: 1–50 billion CFU/day (strain-dependent; higher doses for acute conditions)

See ranked Probiotics products→

• Cochrane review (2019, 34 RCTs, 4,138 participants) found specific probiotics reduced the risk of antibiotic-associated diarrhea by 37%. Lactobacillus rhamnosus GG and Saccharomyces boulardii had the strongest evidence.PubMed ↗
• 2018 meta-analysis of 53 RCTs (5,545 IBS patients) found probiotics significantly improved overall symptoms, abdominal pain, and bloating. Multi-strain formulations tended to outperform single-strain products.PubMed ↗
• Cochrane review (2017, 31 RCTs) found probiotics reduced risk of Clostridioides difficile-associated diarrhea by 60% when given alongside antibiotics. Prevention is more effective than treatment.PubMed ↗
• Effects are highly strain-specific — not all probiotics work for all conditions. Key studied strains: L. rhamnosus GG (antibiotic diarrhea, pediatric gastroenteritis), S. boulardii (C. difficile prevention), VSL#3 / De Simone Formulation (ulcerative colitis), B. infantis 35624 (IBS).
• Generic 'probiotic' labeling without strain specification is a red flag. A product listing 'Lactobacillus acidophilus' without the strain designation cannot claim the benefits of a specific studied strain.

Therapeutic dose: 5–10 g/day (with adequate water)

See ranked Psyllium Husk products→

• 2022 meta-analysis of 16 RCTs found psyllium significantly improved IBS symptom severity, stool consistency, and abdominal pain. Effect size was larger than for other fiber types (bran, methylcellulose).PubMed ↗
• 2019 systematic review confirmed psyllium is the only fiber type consistently recommended by international IBS guidelines (AGA, ACG, NICE). Insoluble fiber (wheat bran) can worsen IBS symptoms.PubMed ↗
• Cochrane review on constipation found psyllium increased stool frequency and improved stool consistency in chronic constipation. Acts as a bulk-forming laxative via water-holding capacity of soluble gel.
• Mechanism: psyllium forms a viscous gel that normalizes stool consistency in both directions — softens hard stools (constipation) and firms loose stools (diarrhea). Also acts as a prebiotic, increasing short-chain fatty acid production.
• Must be taken with ≥240 mL water per dose to prevent esophageal/intestinal obstruction. Start with 2.5 g/day and titrate up to minimize initial bloating.

Therapeutic dose: 250–1,000 mg/day (dried ginger extract)

See ranked Ginger (Zingiber officinale) products→

• Viljoen et al. (2014) meta-analysis of 12 RCTs (1,278 pregnant women) found ginger significantly reduced nausea in early pregnancy compared to placebo, with no increase in adverse events. Effect on vomiting frequency was less consistent.PubMed ↗
• 2018 meta-analysis of 10 RCTs found ginger significantly reduced nausea and vomiting in chemotherapy patients when used as an adjunct to standard antiemetics. 1g/day was the most common effective dose.PubMed ↗
• 2011 RCT (126 participants) found 1,200 mg/day ginger extract accelerated gastric emptying by 25% in healthy volunteers — supporting its use for functional dyspepsia and gastroparesis.PubMed ↗
• Mechanism: gingerols and shogaols act as 5-HT3 receptor antagonists (same mechanism as ondansetron/Zofran) and prokinetic agents. Also inhibits prostaglandin synthesis in gastric mucosa.

Therapeutic dose: 75–150 mg/day zinc-L-carnosine (providing 16–34 mg elemental zinc)

• Mahmood et al. (2007) RCT (10 healthy volunteers) demonstrated zinc-L-carnosine 37.5 mg 2x/day significantly prevented indomethacin-induced gut permeability increase — a model for NSAID-induced gut damage.PubMed ↗
• Approved as a pharmaceutical (Polaprezinc) in Japan since 1994 for gastric ulcer treatment. Multiple Japanese RCTs show accelerated ulcer healing and enhanced mucosal defense.PubMed ↗
• 2020 RCT found zinc-L-carnosine combined with bovine colostrum reduced exercise-induced GI permeability in athletes by 70% — relevant for exercise-induced gut damage.PubMed ↗
• Mechanism: adheres directly to gastric mucosal ulcer sites, stimulates mucosal prostaglandin E2 and epidermal growth factor secretion, and has antioxidant properties. The zinc-carnosine chelate stays intact in the stomach longer than free zinc.

Therapeutic dose: 900–1,500 mg/day (divided into 2–3 doses)

• 2015 RCT (196 IBS-D patients) found berberine 400 mg 2x/day for 8 weeks significantly reduced diarrhea frequency, abdominal pain, and urgency compared to placebo.PubMed ↗
• 2020 study found berberine significantly altered gut microbiome composition — increasing Akkermansia and reducing Clostridium, which may partially explain its metabolic and GI benefits.PubMed ↗
• Used in traditional Chinese medicine for diarrhea for >1,000 years — one of the few traditional uses strongly supported by modern RCTs. Antimicrobial activity against common GI pathogens (E. coli, H. pylori).
• GI side effects (constipation, flatulence, cramping) are common at higher doses. Start at 500 mg/day and titrate. Drug interactions with CYP3A4 substrates should be monitored.

Therapeutic dose: 5,000–15,000 mg/day

See ranked L-Glutamine products→

• 2019 RCT (106 IBS-D patients with increased intestinal permeability) found L-glutamine 5g 3x/day for 8 weeks significantly reduced IBS symptom severity and normalized gut permeability.PubMed ↗
• Glutamine is the primary metabolic fuel for enterocytes (intestinal epithelial cells) and colonocytes. During critical illness or intense exercise, demand exceeds endogenous production.
• 2014 meta-analysis in surgical/critical care patients found glutamine supplementation reduced infectious complications and length of hospital stay. However, the REDOXS trial (2013) found potential harm in critically ill patients with multi-organ failure.
• For gut-focused use (IBS, leaky gut), 5–15g/day is standard. Well-tolerated. Most abundant amino acid in the body — supplementation restores depleted pools during GI stress rather than providing a novel therapeutic effect.

Therapeutic dose: 500–1,500 mg/day standard; 80–200 mg enhanced bioavailability forms

See ranked Curcumin (Turmeric Extract) products→

• 2006 RCT (89 ulcerative colitis patients) found curcumin 1g 2x/day as adjunct to mesalamine significantly improved relapse rate (4.7% vs 20.5% in placebo) over 6 months.PubMed ↗
• 2020 meta-analysis of 7 RCTs found curcumin as adjunctive therapy significantly improved clinical and endoscopic remission rates in ulcerative colitis patients.PubMed ↗
• Mechanism: inhibits NF-kB-mediated intestinal inflammation, reduces COX-2 and TNF-alpha in colonic mucosa, and modulates gut microbiome composition.
• Standard curcumin has very poor oral bioavailability (~1–2%) but paradoxically this may be advantageous for colonic conditions — unabsorbed curcumin reaches the colon in higher concentrations. For colonic targets, standard curcumin may be appropriate.

Therapeutic dose: Varies by enzyme type and activity units (lipase 10,000–40,000 USP units per meal)

• Digestive enzyme replacement (pancrelipase) is FDA-approved and well-established for exocrine pancreatic insufficiency (chronic pancreatitis, cystic fibrosis, post-surgical). This is a distinct clinical indication from general supplementation.
• 2018 RCT (40 healthy subjects) found multi-enzyme supplement did not significantly improve digestion of a standard meal compared to placebo, as measured by breath hydrogen testing.
• Specific enzyme supplementation has evidence for specific conditions: lactase for lactose intolerance, alpha-galactosidase (Beano) for gas from legumes. Broad-spectrum enzyme blends marketed for general 'digestive support' lack clinical support.
• Exception: individuals with low stomach acid (hypochlorhydria, common in elderly and those on PPIs) may benefit from betaine HCl + pepsin supplementation, though RCT evidence is minimal.

Therapeutic dose: 5–10 g/day

See ranked Inulin (Prebiotic Fiber) products→

• 2017 meta-analysis of 12 RCTs found inulin-type fructans (ITF) significantly increased Bifidobacterium populations in the gut. However, changes in microbiome composition did not consistently translate to symptom improvement.PubMed ↗
• Inulin is fermented by colonic bacteria to produce short-chain fatty acids (butyrate, propionate, acetate), which nourish colonocytes and reduce colonic pH. Butyrate is the primary energy source for colonic epithelial cells.
• Major limitation: inulin is a FODMAP and commonly causes bloating, gas, and abdominal discomfort — especially in IBS patients. Doses above 10g/day are poorly tolerated by many individuals. Dose titration starting from 2–3g/day is essential.

Therapeutic dose: 100–300 mg/day (bovine lactoferrin)

See ranked Lactoferrin products→

• 2009 meta-analysis of 3 RCTs found bovine lactoferrin as adjunct to triple therapy improved H. pylori eradication rates by a small but significant margin.PubMed ↗
• 2019 RCT (60 infants) found bovine lactoferrin significantly reduced incidence and severity of acute gastroenteritis. The pediatric GI evidence is stronger than adult data.
• Mechanism: sequesters iron from gut pathogens (bacteriostatic), directly disrupts bacterial membranes (bactericidal), and modulates intestinal immune response. It is a natural component of breast milk and mucosal secretions.

Therapeutic dose: 500–2,000 GDU/day (200–800 mg, taken between meals for systemic effects)

See ranked Bromelain products→

• 2012 review found bromelain reduced stool transit time and improved digestive symptoms in small clinical studies, but most evidence comes from older, poorly designed trials.PubMed ↗
• In vitro studies show bromelain degrades secretory IgA on E. coli fimbriae — potentially reducing bacterial adhesion to intestinal epithelium. Clinical relevance is unproven.
• Better-established evidence exists for bromelain as an anti-inflammatory for sinusitis and post-surgical swelling. Digestive-specific RCTs are few and small.

Therapeutic dose: 320–640 mg/day (standardized to 2.5–5% cynarin)

See ranked Artichoke Extract (Cynara scolymus) products→

• 2015 RCT (247 patients with functional dyspepsia) found artichoke leaf extract significantly reduced dyspepsia severity scores over 6 weeks compared to placebo.PubMed ↗
• 2003 RCT (208 IBS patients) found artichoke extract reduced IBS symptom incidence from 26% to 13% over 2 months — but the trial was unblinded, limiting reliability.PubMed ↗
• Mechanism: cynarin and chlorogenic acid stimulate bile production (choleretic effect), which aids fat digestion. May explain benefit for post-prandial bloating and heaviness. Also has hepatoprotective properties.

Therapeutic dose: 500–1,500 mg/day dried root extract

See ranked Dandelion (Taraxacum officinale) products→

• No human RCTs have tested dandelion specifically for digestive outcomes. The evidence base rests entirely on traditional use, in vitro studies, and animal models.
• Animal studies show dandelion root extract increases bile secretion and has mild laxative properties. In vitro, it demonstrates prebiotic effects (promoting inulin-fermenting Bifidobacteria).
• EFSA (European Food Safety Authority) rejected health claims for dandelion and digestive function in 2011 due to insufficient evidence. Widely used in traditional European and Chinese herbal medicine but this does not substitute for clinical evidence.